Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

FASN inhibitor

DRUG CLASS:

FASN inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	TVB-2640 Sensitive: C2 – Inclusion Criteria TVB-2640 Sensitive : C2	TVB-2640 Sensitive: C2 – Inclusion Criteria TVB-2640 Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	TVB-2640 Sensitive: C3 – Early Trials TVB-2640 Sensitive : C3	TVB-2640 Sensitive: C3 – Early Trials TVB-2640 Sensitive : C3
KRAS mutation	Breast Cancer	KRAS mutation	Breast Cancer	TVB-2640 Sensitive: C3 – Early Trials TVB-2640 Sensitive : C3	TVB-2640 Sensitive: C3 – Early Trials TVB-2640 Sensitive : C3
KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	FASN inhibitor Sensitive: D – Preclinical FASN inhibitor Sensitive : D	FASN inhibitor Sensitive: D – Preclinical FASN inhibitor Sensitive : D
KRAS G12C	Lung Adenocarcinoma	KRAS G12C	Lung Adenocarcinoma	adagrasib + TVB-3664 Sensitive: D – Preclinical adagrasib + TVB-3664 Sensitive : D	adagrasib + TVB-3664 Sensitive: D – Preclinical adagrasib + TVB-3664 Sensitive : D